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Abstract
Background: Resorbable bone hemostasis materials, oxidized regenerated cellulose (ORC) and microfibrillar
collagen (MFC), remain at the site of application for up to 8 weeks and may impair osteogenesis. Our experimental
study compared the effect of a water-soluble alkylene oxide copolymer (AOC) to ORC and MFC versus no
hemostatic material on early bone healing.
Methods: Two circular 2.7 mm non-critical defects were made in each tibia of 12 rabbits. Sufficient AOC, ORC or
MFC was applied to achieve hemostasis, and effectiveness recorded. An autologous blood clot was applied to
control defects. Rabbits were sacrificed at 17 days, tibiae excised and fixed. Bone healing was quantitatively
measured by micro-computed tomography (micro-CT) expressed as fractional bone volume, and qualitatively
assessed by histological examination of decalcified sections.
Results: Hemostasis was immediate after application of MFC and AOC, after 1-2 minutes with ORC, and >5
minutes for control. At 17 days post-surgery, micro-CT analysis showed near-complete healing in control and AOC
groups, partial healing in the ORC group and minimal healing in the MFC group. Fractional bone volume was 8
fold greater in the control and AOC groups than in the MFC group (0.42 ± 0.06, 0.40 ± 0.03 vs 0.05 ± 0.01, P <
0.001) and over 1.5-fold greater than in the ORC group (0.25 ± 0.03, P < 0.05). By histology, MFC remained at the
application site with minimal healing at the defect margins and early fibrotic tissue within the defect. ORC-treated
defects showed partial healing but with early fibrotic tissue in the marrow space. Conversely, control and AOC-
treated defects demonstrated newly formed woven bone rich in cellular activity with no evidence of AOC
remaining at the application site.
Conclusions: Early healing appeared to be impaired by the presence of MFC and impeded by the presence of
ORC. In contrast, AOC did not inhibit bone healing and suggest that AOC may be a better bone hemostatic
material for procedures where bony fusion is critical and immediate hemostasis required.
Background
Choosing an effective bone hemostasis material poses a
unique challenge. The surgeon must weigh the efficacy,
immediacy and ease of use of the material against
potential unintended consequences associated with the
material such as adverse effects on bone healing. Com-
monly used hemostatic agents encompass nonresorbable
materials such as softened beeswax and resorbable
materials manufactured from plants (e.g., cellulose),
animal products (e.g., collagen), or synthetic polymers
(e.g., alkylene oxide copolymers) [1]. All topical hemo-
static agents have distinct advantages and disadvantages
and a recent comprehensive review by Achneck and col-
leagues [1] provides the surgeon with a selection guide
based on the agent’s mechanism of action, efficacy and
potential adverse effects.
Bonewax is composed primarily of beeswax, a hydro-
phobic and non-resorbable material. Bonewax remains
at the implantation site indefinitely and is well known
to inhibit bone growth as demonstrated in numerous
animal [2-8] and clinical studies [9-13]. Although bone
wax is effective in achieving immediate bone hemostasis
by means of tamponade, clinicians are increasingly
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resorb or dissolve from the site of application [1,14].
Two commonly used resorbable materials are oxidized
regenerated cellulose (ORC), composed of polyanhydro-
glucuronic acid derived from wood pulp [15,16], and
microfibrillar collagen (MFC), an animal product
derived from purified bovine hide corium [17,18]. Both
materials are actively degraded in vivo and are reported
to be removed from the site of application within 6
weeks to still being present after 1 year [19,20] for ORC
or within 45 to 90 days [3,21] for MFC.
Alkylene oxide copolymer (AOC) is a synthetic bone
hemostasis material composed of water-soluble copoly-
mers [14]. AOC is a hydrophilic waxy material that sticks
well to wet surfaces, which makes it well-suited for bone
hemostasis. Alkylene oxide copolymers have a long history
of use in the medical and pharmaceutical fields [22-24];
they are biocompatible, chemically inert, non-metaboliz-
able and are eliminated from the body unchanged primar-
ily via renal excretion [25,26]. AOC dissolves from the site
of application within 48 hours [8,24].
Resorbable bone hemostasis materials are often
selected because of their perceived lack of interference
with bone healing. Previous studies of bone healing in
the presence of hemostatic agents have produced con-
flicting results, with conclusions often based on histolo-
gical observations rather than quantitative measurement
of bone growth [16].
This paper compares the hemostatic properties and
effects on bone healing of AOC, ORC and MFC. The
products ORC and MFC were selected because they are
often used in surgery for bone hemostasis, and presum-
ably it is assumed that ORC and MFC do not signifi-
cantly interfere with bone healing because they are
resorbable. However, as AOC dissolves from the site of
application within 2 days compared to weeks/months
for ORC and MFC, we hypothesized that AOC would
permit faster bone healing than other resorbable hemo-
static agents, and designed the current study to test this
hypothesis. The animal model was designed to evaluate
the effects of these agents on early healing of a non-cri-
tical size bone defect. Both bone quantity and quality
were evaluated by micro-CT and histology.
The objective of this study is to provide quantitative
data on early bone healing following application of
resorbable bone hemostasis materials with an aim to
better assist the surgeon in selection of an effective
bone hemostatic material for procedures where bony
fusion is critical and early healing is desired.
Methods
Materials
Three resorbable hemostatic agents were used for
this study: Alkylene oxide copolymer ("AOC”, Ostene®,
Ceremed Inc., Los Angeles, California); oxidized regen-
erated cellulose ("ORC”, Surgicel®, Ethicon Inc., Somer-
ville, New Jersey); and microfibrillar bovine collagen
("MFC”, Avitene®, Davol Inc., Warwick, Rhode Island).
Rabbit Tibia Defect Model
The animal protocol was approved by the Institutional
Animal Care and Use Committee at the University of
Southern California, in conformity with the NIH-guide-
lines for the care and use of laboratory animals (DHHS
publication No. [NIH] 85-23 revised 1996).
Micro-computed tomography (micro-CT) analyses of
non critical-size bilateral bone defects were performed
based on previous studies [6,27]. Twelve 2.5 kg male
New Zealand White rabbits were used for this study,
randomized into four treatment groups (2 defects per
tibia, 4 defects per animal, 12 defects per group). Rab-
bits were anesthetized with a subcutaneous injection of
ketamine/xylazine (90/10 mg/kg) and anesthesia main-
tained with 1% isoflurane. Surgery was performed using
standard aseptic techniques. Tibiae were exposed and
two 2.7 mm circular defects approximately 1 cm from
the proximal extremity were created in each tibia with a
high torque, low speed trephine drill under constant sal-
ine irrigation. Sufficient hemostatic material was applied
to the defect to achieve hemostasis. For control rabbits
(i.e., no hemostatic material applied), autologous blood
was drawn from the ear artery prior to the surgical pro-
cedure into a 1 mL polypropylene syringe without any
anticoagulant, thrombin was added to blood sample to
promote clot formation and the formed clot was applied
to the defect. The same hemostatic material was used
for each of the two circular defects per tibia; different
treatments were used for left and right tibiae per animal.
The wounds were then closed with non-resorbable
monofilament sutures. All animals were given a subcuta-
neous injection of buprenorphine (0.05 mg/kg) immedi-
a t e l ya f t e rs u r g e r ya n de v e r y1 2h o u r sf o r2d a y sp o s t -
surgery. Rabbits were monitored daily for the first five days
and every two days thereafter for any adverse events during
the 17 days post-surgical housing.
At 17 days post-surgery, rabbits were sacrificed using
an intravenous overdose of pentobarbital and the tibiae
were excised. The tibiae were placed in neutral buffered
formalin for 48 h, washed in water and then trimmed to
2 - 3 cm sections (approximately to 0.5 cm above and
below the defect site). After trimming, the tibiae were
stored in 70% ethanol.
Evaluation of Bleeding or Hemostasis
After application of a hemostatic material (or pre-
formed blood clot for control defects), observations
were recorded for a minimum period of 5 minutes,
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of hemostasis over the observation period.
Micro-CT Analysis
Excised, fixed tibiae were immobilized in a scanning
tube using a 30% (w/w) optically-clear solution of Pluro-
nic F108 as described previously [28]. In brief, a scan-
ning tube was half-filled with cold F108 solution (below
the gelation temperature of 17°C) and allowed to gel at
room temperature. Tibiae were inserted into the gel in
the desired orientation, after which the tube was then
filled up with cold F108 solution and allowed to gel.
Tibiae were scanned in F108 gel using a Scanco40
scanner (micro-CT-40 Scanco Medical, Bassersdorf,
Switzerland) with a voxel isotropic resolution of 15 μm
and an X-ray energy of 55 KVp and 72 μA.
Two tibiae were accommodated in the scanning tube
for each scan. The scan time was about 3 h and
accounted for 1000 projections/180°, 200 ms integration
time, and 2048 CCD detector array. A calibration phan-
tom of hydroxyapatite was used. Segmented images
were obtained using a Gaussian filter sigma = 1.2 and
support = 1. Threshold for the image binarization was
set as 25% of the maximal grayscale for all the scans.
Volumetric analysis was performed by obtaining
volumes of interest, using the dedicated Scanco software
t oi n c l u d eo n l yt h em i n e r a l i z e dt i s s u ef o r m e di n w a r d
during healing and separated from the rest of the tibia
(i.e., 1.35 mm radius from center of defect).
The architectural parameters obtained from the binar-
ized volumes of interest were:
total volume (TV, mm
3), bone volume (BV, mm
3), and
bone volume fraction (BV/TV). Bone mineral density
(BMD, mgmL
-1) of mineralized tissue within the volume
of interest was also measured.
T Vi st h ev o l u m eo ft h ew h o l ed e f e c t( 2 . 7m md i a -
meter), BV represents the volume of the mineralized tis-
sue formed during healing and BV/TV is the relative
bone volume which normalizes the volume of the
mineralized tissue formed during healing by taking into
account differences in thickness of the specimen. BMD
is the density of mineralized tissue within the volume of
interest, and is an indicator of the quality of mineralized
tissue.
Histology
Following micro-CT analysis, fixed tibiae were decalci-
fied by immersion in excess 12 wt% hydrochloric acid
(Decalcifier II®, Surgipath Medical Industries Inc., Rich-
mond IL) for approximately 5 days, wax embedded, and
5 μm sections of decalcified tibiae were cut approxi-
mately 200 μm from the outer edge of the defects and
near the center of the defects (approximately 1.4 mm
from the outer edge).
Serial sections were stained with hemotoxylin and
eosin (H&E) and with modified Masson’s trichrome-
elastic van Gieson (EVG) for collagen visualization.
With the trichrome-EVG stain, mineralized bone is seen
as red, and Type 1 collagen stains blue. Type 1 collagen
is present both in fibrous or scar tissue (composed of
fibrocytes or fibroblasts inaT y p e1c o l l a g e nm a t r i x )
and in newly formed woven bone. The woven bone typi-
cally stains darker blue than fibrous tissue, and can also
be recognized by its location and architecture.
Adjacent sections were stained with H&E vs. tri-
chrome-EVG for appropriate comparison between
images (5 μm distance between stain pairings).
Photomicrographs of sections were obtained using a
ScanScope XT System (Aperio Technologies Inc, Vista,
CA) at x20 magnification. Sections were examined by an
expert who was blinded to the three treatment groups
for mineralized bone quality, cellular activity including
osteoblasts and osteoid, as well as any evidence of fibro-
tic tissue formation within the defect site.
Statistics
Architectural micro-CT values (BV, TV, BV/TV) were
reported as means and standard errors. BV/TV results
were compared by the Tukey’s Multiple Comparison
Test (Prism; GraphPad Software Inc., San Diego, CA). A
P value of <0.05 was considered statistically significant.
Results
Hemostasis was achieved immediately after application
of AOC and MFC, and was maintained for the five min-
ute observation period. No differences were noted
between AOC or MFC. Hemostasis was achieved
between 1 and 2 minutes after application of ORC, and
was also maintained for the five minute observation per-
iod. A period of greater than 5 minutes was required for
control defects to achieve hemostasis (from 10 to about
30 minutes). Post-surgery, all rabbits were healthy with
good appetites and showed signs of good healing with
no evidence of complications (e.g., hematoma, infection).
Examples of a cross-section through the center of the
defect and a micro-CT derived outer view of minera-
lized tissue within a representative defect from each
group are shown in Figure 1 (left column). The cross-
sectional views show varying amounts of irregular radio-
opacity in control, AOC- and ORC-treated defects
respectively representing new bone formation. The MFC
treated defects have clearly-defined margins indicating
the absence of any new bone formation. These observa-
tions are reflected in the micro-CT derived 3-D refor-
mulated images of mineralized tissue showing
substantial, well developed mineralization in the control
and AOC-treated defects, a more diffuse structure of
mineralization in the ORC-treated defects and a virtual
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Figure 1 Representative micro-CT images of excised rabbit tibiae at 17 days post-surgery. Left column: Cross-section views through the
center of the defect showing newly formed bone as slightly opaque in untreated (control), alkylene oxide copolymer- and oxidized regenerated
cellulose-treated defects, and an absence of opacity in microfibrillar collagen-treated defects (bar = 5.0 mm). Center and right columns: micro-
CT generated binarized images of mineralized tissue of the defect area (center) and area analyzed within the defect (right). AOC-treated and
untreated (control) defects show substantial, well developed mineralized tissue, ORC-treated defect shows a more diffuse structure of mineralized
tissue, and minimal mineralized tissue is observed within the MFC-treated defect.
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(Figure 1, center and right column). Micro-CT derived
quantitative architectural parameters are shown in
Table 1 and Figure 2. The tissue volume (TV) analyzed
for each defect was comparable for all defect groups
(Table 1). Normalization of the measured mineralized
bone volume (BV) by TV, showed no difference in
mineralization between AOC-treated and control defects
(Figure 2) yielding fractional bone volume (BV/TV) in
the following order Control = AOC > ORC >> MFC
with BV/TV values of 0.40, 0.42, 0.25 and 0.05 respec-
tively (Figure 2). Mineralization (Figure 2) in the AOC-
treated and control defects was markedly higher than
MFC-treated defects (8-fold difference, p <0.001) or
ORC-treated defects (1.5 fold difference, p <0.05). ORC-
treated defects showed more mineralization than MFC-
treated defects (5 fold difference, p <0.01). The bone
mineral density measured within the defects were com-
parable between all groups, indicative that the quality of
new bone formed was consistent for all treatment
groups (Table 1).
Representative 5 μm thick demineralized histology
slices are shown in Figures 3, 4, 5 and 6, stained with
H&E (upper panels) or trichrome-EVG at ×2 (left
panels) and ×10 magnification. For untreated (control)
and AOC-treated defects, much of the defect area is
filled with newly formed woven bone rich in cellular
activity, with no evidence of fibrotic scar tissue (Figures
3 and 4) nor residual polymer (Figure 4). Trichrome-
EVG stained sections highlight Type 1 collagen within
the areas of newly formed woven bone throughout the
defect, indicative of good healing and an absence of
fibrotic scar tissue (Figures 3 and 4). For ORC-treated
defects (Figure 5), approximately half of the defect area
is filled with newly formed woven bone and native col-
lagen mesh, with the remaining portions showing early
fibrotic tissue.
H&E and trichrome-EVG staining of MFC-treated
defects (Figure 6) demonstrate negligible new bone for-
mation with the margin of the defect clearly visible and
evidence of early fibrotic tissue (dense collagen mesh)
within the defect. The trichrome-EVG stain clearly
demonstrates the presence of residual MFC hemostatic
material within the marrow space of the tibia, seen as
dense organized collagen bundles stained blue, and
native collagen meshwork to a lesser extent as observed




Bone defects in animal studies that test efficacy of an
agent intended to facilitate bony repair require a defect
large enough to preclude spontaneous healing. In con-
trast, testing of hemostatic agents should be performed
on defects smaller than a critical size, as such models
demonstrate the effects of these agents on bone healing
[18]. In our study, the 2.7 mm defect was non-critical,
and could be created reproducibly with precision. The
time point chosen reflects a point at which the defect
would be largely healed on gross inspection but lacking
complete mineralization within the defect, and at which
micro-CT could detect the greatest differences between
test groups. As a precise method to assess healing,
micro-CT is an effective technique to quantitate minera-
lization within a defect as shown in calvarial bone
defects in a rat model after application of bonewax
or AOC compared to no hemostatic material [6].
Micro-CT derived volume fraction of bone provides
an accurate measure of mineralized tissue within a
3-dimensional volume of interest as opposed to
Table 1 Micro-CT derived architectural parameters for
2.7 mm circular defects at 17 days post-surgery.
MEASURE CONTROL AOC ORC MFC
Average SEM Average SEM Average SEM Average SEM
TV (mm
3) 5.10 0.18 5.34 0.22 4.77 0.10 5.18 0.14
BV (mm




696.6 10.7 665.6 11.4 637.1 8.8 669.2 12.2
Key: TV = volume of the whole defect; BV = mineralized tissue; BMD = density
of mineralized tissue within the volume of interest.
Figure 2 Bone mineralization at 17 days post-surgery.M e a n
values for micro-CT derived fractional bone volume (BV/TV) showing
an 8 fold greater BV/TV value for untreated (control) and alkylene
oxide copolymer-versus microfibrillar collagen-treated defects (0.42
± 0.06, 0.40 ± 0.03 vs 0.05 ± 0.01 respectively, P < 0.001) and over
1.5 fold greater BV/TV value versus oxidized regenerated cellulose-
treated defects (0.25 ± 0.03, P < 0.05). Number of defects per group
= 12, P values determined from Tukey’s Multiple Comparison Test.
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Page 5 of 12Figure 3 Microscopy of control defects at 17 days post-surgery. Untreated (Control) adjacent 5 μm demineralized bone sections stained
with H&E (upper) and Trichrome-EVG at ×2 (left) and ×10 magnification. The edge of the defect is identified with black/green arrows, and the
area of magnification shown with a dotted box. Defects show good healing with newly formed woven bone (light blue arrows) rich in cellular
activity (osteoid shown with dark blue arrows). Blue stars indicate native collagen meshwork throughout the tissue.
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Page 6 of 12Figure 4 Microscopy of alkylene oxide-treated defects at 17 days post-surgery. Alkylene oxide copolymer-treated adjacent 5 μm
demineralized bone sections stained with H&E (upper) and Trichrome-EVG at ×2 (left) and ×10 magnification. The edge of the defect is
identified with black/green arrows, and the area of magnification shown with a dotted box. Defects show good healing with newly formed
woven bone (light blue arrows) rich in cellular activity (osteoid shown with dark blue arrows). Blue stars indicate native collagen meshwork
throughout the tissue.
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Page 7 of 12Figure 5 Microscopy of oxidized regenerated cellulose-treated defects at 17 days post-surgery. Oxidized regenerated cellulose-treated
adjacent 5 μm demineralized bone sections stained with H&E (upper) and Trichrome-EVG at ×2 (left) and ×10 magnification. The edge of the
defect is identified with black/green arrows, and the area of magnification shown with a dotted box. Defects show partial healing with newly
formed woven bone (light blue arrows) rich in cellular activity (osteoid shown with dark blue arrows). Early fibrotic tissue is observed within the
defect (white stars). Blue stars indicate native collagen meshwork within the marrow and defect.
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Page 8 of 12Figure 6 Microscopy of microfibrillar collagen-treated defects at 17 days post-surgery. Microfibrillar collagen-treated adjacent 5 μm
demineralized bone sections stained with H&E (upper) and Trichrome-EVG at ×2 (left) and ×10 magnification. The edge of the defect is
identified with black/green arrows, and the area of magnification shown with a dotted box. Defects show minimal healing with no evidence of
newly formed woven bone. Dense bundles of residual collagen are observed (yellow arrows) and early fibrotic tissue within the marrow space
(white stars). Blue stars indicate native collagen meshwork within the marrow space.
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based (2-D) measurements of undemineralized histologi-
cal sections [27]. For this stu d yw ec h o s ear a b b i tt i b i a l
defect as we were interested in using a long bone defect
and a larger animal. The mineralized bone fraction can
be directly correlated with torsional rigidity in a murine
femur fracture model [29].
Bone hemostasis
Both AOC and MFC achieved immediate and effective
bone hemostasis. MFC required the use of an instru-
ment for application to the defect whereas placement of
AOC was simplest using a gloved finger. Oxidized
regenerated cellulose achieved hemostasis 1-2 minutes
after application. Effective hemostasis was maintained
following application of all three hemostatic materials
studied.
Alkylene oxide copolymer
AOC is a hydrophilic waxy material that sticks well to
wet surfaces, which makes it well-suited for bone
hemostasis. Similar to bonewax, AOC achieves immedi-
ate hemostasis by tamponade and does not act bio-
chemically [1,14,24], AOC polymer dissolves from the
site of application within 48 hours [14,24] and is
excreted unchanged primarily via renal filtration [25,26].
In this study, micro-CT analysis showed normal early
bone healing in tibiae after the use of AOC, confirmed
by histological analysis when compared to control
defects where no hemostatic material was applied. This
finding is consistent with earlier reports for the use of
AOC for bone hemostasis [6-8]. Magyar et al. analyzed
bone healing in a rat calvaria defect model using micro-
CT, and found that AOC treated defects healed as well
as, and possibly earlier than controls [6]. In a study
employing a rabbit iliac crest defect model, the authors
concluded that AOC does not interfere with bone heal-
ing at 6 weeks when evaluated using light microscopy
[30]. A water-soluble AOC wax comprised solely of
poloxamers (polyoxyethylene-polyoxypropylene-polyox-
yethylene triblock copolymers) was an effective bone
hemostasis material that was not evident at the implan-
tation site at 72 hours, showed good healing as early as
10 days post-surgery and healing was comparable to
untreated defects up to 42 days in a rat femur defect
model as determined by X-ray and histological analyses
[24].
Oxidized regenerated cellulose
ORC relies upon multiple mechanisms of action for
hemostasis, including physical and mechanical actions in
tamponade, and surface interactions with proteins, pla-
telets. ORC may also promote hemostasis chemically
due to its low pH, which generates a brownish artificial
clot containing acid hematin. ORC inhibited early bone
healing in our study as compared to control and AOC
(P < 0.05), but less so than MFC (P < 0.01). This finding
is consistent with a number of previous animal studies
[5,16,31]. Ibarrola et al. [5] examined bone healing in a
rat tibial defect at multiple time points using light
microscopy. ORC caused an intense inflammatory
response and impaired osseous regeneration with resi-
dual material still present in the defects after 120 days
[5]. These adverse effects were present to a lesser degree
even when ORC was removed at the time of surgery [5].
Conversely, Finn et al., found no residual ORC two
months after application in a canine iliac crest defect
model and did not observe any adverse effects on bone
regeneration on microscopic examination [3]. In a more
recent study, Dias et al. employed histomorphological
techniques to compare the effect of laboratory grade
oxidized cellulose with a Type 1 bovine collagen sponge
on bone healing in a 4 mm diameter bone defect sheep
model. Although little difference was reported between
the two groups, and bone healing was assessed as com-
plete after 6 to 8 weeks, no control group was included
in the study [15].
Microfibrillar collagen
The classical powder form of MFC is a microcrystalline,
water-insoluble, partial acid salt of collagen [17]. It is a
dry, fluffy fleece that adheres well to bleeding surfaces
and provides immediate hemostasis [1,18]. The hemo-
static properties of MFC rely on the promotion of plate-
let aggregation as well as physically blocking bleeding
vessels. Advantages of collagen fleece are: fast induction
of hemostasis; low tissue reaction; and rapid resorption
[16]. A major disadvantage of using collagen fleece is
difficulty in manipulating the agent when attempting to
apply it to the area of bleeding [1]. MFC is actively
degraded in vivo and is reported to be removed from
the site of application in 45 to 90 days [1,3,21]. The sur-
prising finding of our study is the almost complete
absence of bone healing 17 days following application of
MFC, an effect similar to that observed with the use of
nonresorbable bone wax [6]. The histological images for
MFC-treated defects show a clearly defined defect mar-
gin indicating that minimal healing occurred over the 17
post-surgical days. These findings are consistent with
histological evaluation of rabbit cranial defects filled
with MFC that were shown to be significantly larger
than untreated control defects at 4 and 7 weeks post-
surgery [32].
In contrast, other authors have found little or no
adverse effect of MFC on bone healing at time points in
excess of 2 months based on qualitative observations
using histological techniques [3,17,33]. Cobden et al.
performed osteotomies of the greater trochanter in a
Armstrong et al. BMC Surgery 2010, 10:37
http://www.biomedcentral.com/1471-2482/10/37
Page 10 of 12canine model and found no evidence that MFC inter-
fered with bone healing at three months [17]. In a study
that employed a 5 mm rat tibial defect, residual MFC
material was found in the defects at 90 days, although
the authors concluded MFC did not impede bone heal-
ing since the bone defects had healed at 60 days [33]. In
a subsequent study, Finn et al. examined the effects
MFC on osseous regeneration in a canine iliac crest
defect model. On qualitative microscopic examination
after 2 months residual MFC was observed in the
defects, but no adverse effects on bone regeneration was
noted [3].
Our study investigated the effect of MFC on early
bone healing at 17 days post-surgery, which may explain
the discrepancy between our findings and those of other
authors at much longer post-surgical time points
[3,17,33]. Although effective at achieving immediate and
effective hemostasis, the adverse effect of MFC on
osteogenesis would suggest that this agent would impair
healing in the clinical setting, and this finding is in
agreement with the recommendation that MFC should
be removed from the site of application as it interferes
with bone healing [16].
Conclusion
Microfibrillar collagen and alkylene oxide copolymer
achieved immediate and effective bone hemostasis. Oxi-
dized regenerated cellulose achieved hemostasis 1-2
minutes after application. Effective hemostasis was
maintained following application of all three hemostatic
materials studied. In our model, early bone healing was
significantly impaired by the presence of microfibrillar
collagen and impeded by the presence of oxidized
regenerated cellulose. Alkylene oxide copolymer did not
inhibit bone healing when compared to untreated (con-
trol) defects and thus may be a good clinical agent in
cases where bony fusion is critical and where immediate
hemostasis is required.
Our results confirm the use of alkylene oxide copoly-
mer does result in faster bone healing compared to
either oxidized regenerated cellulose or microfibrillar
collagen, presumably because AOC is cleared from the
bone defect much earlier.
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